Dr. Reddy’s Laboratories launches Toripalimab in India

Dr. Reddy’s Laboratories (NYSE:RDY) has announced the launch of Toripalimab, the first immuno-oncology drug approved in India for the treatment of nasopharyngeal carcinoma (NPC).

The approval of Toripalimab, marketed under the brand name Zytorvi®, offers a groundbreaking therapeutic option for patients battling this aggressive form of cancer, making India the third country to gain access to the drug after international regulatory approvals.

In a statement, M.V. Ramana, CEO of Branded Markets at Dr. Reddy's Laboratories, called the launch a "significant milestone for patients diagnosed with nasopharyngeal carcinoma (NPC) in India."

He added that the drug’s introduction reflects the company's ongoing commitment to enhancing cancer care in emerging markets.

Toripalimab has already been approved by key global regulatory bodies for treating recurrent or metastatic NPC.

Clinical trials have shown that the drug reduces the risk of progression or death by 48%, offering renewed hope to patients who previously faced limited treatment options.

The launch in India follows a strategic licensing agreement between Dr. Reddy’s and Shanghai Junshi Biosciences Co., which holds the rights to develop and commercialize Toripalimab outside of China.